Whole genome sequencing identifies rare genetic variants in familial pancreatic cancer patients
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal malignancies with very high mortality and short survival time. About 5–10% of the PDAC patients have a familial predisposition to the disease designated as familial pancreatic cancer (FPC), suggesting genetic modulation of FPC...
Saved in:
Published in | Annals of human genetics Vol. 86; no. 4; pp. 195 - 206 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.07.2022
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal malignancies with very high mortality and short survival time. About 5–10% of the PDAC patients have a familial predisposition to the disease designated as familial pancreatic cancer (FPC), suggesting genetic modulation of FPC pathogenesis. It is estimated that currently identified sequence variants account for less than 20% of the genetic basis of FPC leaving the majority of the genetic architecture unclarified. We performed whole genome sequencing (WGS) analysis on benign formalin‐fixed paraffin‐embedded (FFPE) tissues from 35 FPC patients focusing on genes enriched by rare and functional sequence variants. We identified 40 genes hosting at least 2 protein truncating variants (PTVs). Significant overlaps of the 40 genes were found (p < 1 × 10–22) with cancer genes, cancer driver genes and genes found in previous studies on cancer, including ATM, POLE, BRCA2, TYR03, PABPC1 and SSC5D. The PTV genes are significantly overrepresented in biological pathways in cancer development and progression including extracellular matrix organization, signaling by RHO GTPases and RHO GTPase cycle. Association analysis using external controls detected 6 genes with p < 0.05. The WGS analysis revealed high heterogeneity in the detected rare variants among FPC patients and provides novel genes harboring potential mutational hotspots for future validation and replication. |
---|---|
Bibliography: | This project was jointly supported by: The Danish Cancer Society (ref.: R218‐A13150), NEYE Fonden, Odense Pancreas Center (OPAC), Odense University Hospital Research Fund, The Danish Cancer Research Fund (Dansk Kræftforskningsfond), Fonden til Lægevidenskabens Fremme (A.P. Møller Fonden), Fabrikant Einar Willumsens Mindelegat, the Rigshospitalet (RH)/Odense University Hospital (OUH) Research Fund (ref.: A3183), Aase og Ejnar Danielsens Fond (ref.: 18‐10‐0686). Funding Information ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0003-4800 1469-1809 |
DOI: | 10.1111/ahg.12464 |